Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Alecensaro | Alectinib | Locally advanced or metastatic ALK+ NSCLC (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Alecensaro | Alectinib | Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Alecensaro | alectinib | ALK-positive NSCLC | Active | |||
Alimta | Pemetrexed | Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | |||
Aloxi (capsule) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list | Complete | ||
Aloxi (injection) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list at the submitted price | Complete | ||
Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete | ||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled |